Mitochondrial Calcium Deficit Links Structural Remodeling to Atrial Fibrillation — and an Old Cholesterol Drug, Ezetimibe, Shows Unexpected Anti‑AF Potential
Posted inCardiology news

Mitochondrial Calcium Deficit Links Structural Remodeling to Atrial Fibrillation — and an Old Cholesterol Drug, Ezetimibe, Shows Unexpected Anti‑AF Potential

New human tissue and cellular data implicate impaired mitochondrial Ca2+ uptake, structural uncoupling of sarcoplasmic reticulum–mitochondria contacts, and oxidative stress in atrial fibrillation (AF); ezetimibe restored mitochondrial Ca2+ handling and reduced AF burden in exploratory analyses.
Urolithin A in Elite Distance Runners: Improves Recovery and Perceived Effort but Not Race Performance in 4-Week Altitude Training
Posted inInternal Medicine news Public Health

Urolithin A in Elite Distance Runners: Improves Recovery and Perceived Effort but Not Race Performance in 4-Week Altitude Training

A randomized, placebo-controlled trial in highly trained male distance runners found 4 weeks of 1000 mg/day urolithin A reduced markers of muscle damage and perceived exertion and upregulated mitochondrial proteomic pathways, but did not produce statistically significant performance gains in a 3000 m time trial.
Urolithin A for Muscle Health: A 4‑Month Randomized Trial Shows Improved Lower‑Limb Strength, Endurance Signals, and Mitochondrial Biomarkers
Posted inClinical Updates Family Medicine & Nutrition Internal Medicine news Specialties

Urolithin A for Muscle Health: A 4‑Month Randomized Trial Shows Improved Lower‑Limb Strength, Endurance Signals, and Mitochondrial Biomarkers

In a randomized, double‑blind 4‑month trial of middle‑aged overweight adults, oral urolithin A improved hamstring strength (~10–12%), increased peak VO2 and 6‑minute walk distance (clinically meaningful at 33 m for 1,000 mg), altered mitochondrial proteomic signatures, and reduced inflammation without major safety signals.